QQQ   280.53 (-0.41%)
AAPL   140.94 (-1.38%)
MSFT   244.37 (-0.31%)
META   113.93 (-0.17%)
GOOGL   94.94 (-2.10%)
AMZN   88.46 (+0.24%)
TSLA   174.04 (-3.21%)
NVDA   161.20 (+0.83%)
NIO   12.58 (-4.98%)
BABA   88.33 (-3.41%)
AMD   70.14 (-0.19%)
T   19.30 (+0.68%)
MU   53.82 (+0.26%)
CGC   3.24 (-10.25%)
F   13.10 (-1.36%)
GE   85.00 (-0.33%)
DIS   92.15 (-0.15%)
AMC   6.05 (-10.37%)
PYPL   74.42 (+3.03%)
PFE   50.24 (+1.07%)
NFLX   308.42 (+0.94%)
QQQ   280.53 (-0.41%)
AAPL   140.94 (-1.38%)
MSFT   244.37 (-0.31%)
META   113.93 (-0.17%)
GOOGL   94.94 (-2.10%)
AMZN   88.46 (+0.24%)
TSLA   174.04 (-3.21%)
NVDA   161.20 (+0.83%)
NIO   12.58 (-4.98%)
BABA   88.33 (-3.41%)
AMD   70.14 (-0.19%)
T   19.30 (+0.68%)
MU   53.82 (+0.26%)
CGC   3.24 (-10.25%)
F   13.10 (-1.36%)
GE   85.00 (-0.33%)
DIS   92.15 (-0.15%)
AMC   6.05 (-10.37%)
PYPL   74.42 (+3.03%)
PFE   50.24 (+1.07%)
NFLX   308.42 (+0.94%)
QQQ   280.53 (-0.41%)
AAPL   140.94 (-1.38%)
MSFT   244.37 (-0.31%)
META   113.93 (-0.17%)
GOOGL   94.94 (-2.10%)
AMZN   88.46 (+0.24%)
TSLA   174.04 (-3.21%)
NVDA   161.20 (+0.83%)
NIO   12.58 (-4.98%)
BABA   88.33 (-3.41%)
AMD   70.14 (-0.19%)
T   19.30 (+0.68%)
MU   53.82 (+0.26%)
CGC   3.24 (-10.25%)
F   13.10 (-1.36%)
GE   85.00 (-0.33%)
DIS   92.15 (-0.15%)
AMC   6.05 (-10.37%)
PYPL   74.42 (+3.03%)
PFE   50.24 (+1.07%)
NFLX   308.42 (+0.94%)
QQQ   280.53 (-0.41%)
AAPL   140.94 (-1.38%)
MSFT   244.37 (-0.31%)
META   113.93 (-0.17%)
GOOGL   94.94 (-2.10%)
AMZN   88.46 (+0.24%)
TSLA   174.04 (-3.21%)
NVDA   161.20 (+0.83%)
NIO   12.58 (-4.98%)
BABA   88.33 (-3.41%)
AMD   70.14 (-0.19%)
T   19.30 (+0.68%)
MU   53.82 (+0.26%)
CGC   3.24 (-10.25%)
F   13.10 (-1.36%)
GE   85.00 (-0.33%)
DIS   92.15 (-0.15%)
AMC   6.05 (-10.37%)
PYPL   74.42 (+3.03%)
PFE   50.24 (+1.07%)
NFLX   308.42 (+0.94%)

Sight Sciences, Inc. (NASDAQ:SGHT) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Sight Sciences, Inc. (NASDAQ:SGHT - Get Rating) have been assigned an average rating of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $12.00.

A number of equities research analysts recently weighed in on the company. Needham & Company LLC assumed coverage on Sight Sciences in a research note on Tuesday, October 4th. They issued a "hold" rating on the stock. Piper Sandler decreased their price objective on Sight Sciences from $17.00 to $15.00 and set an "overweight" rating on the stock in a report on Friday, August 12th. Bank of America initiated coverage on Sight Sciences in a report on Tuesday, October 11th. They issued a "neutral" rating on the stock. Morgan Stanley upped their price objective on Sight Sciences from $10.00 to $11.00 and gave the company an "overweight" rating in a report on Friday, November 11th. Finally, Citigroup upped their price objective on Sight Sciences to $10.00 in a report on Wednesday, November 16th.

Institutional Trading of Sight Sciences

Several large investors have recently bought and sold shares of SGHT. Swiss National Bank raised its position in Sight Sciences by 7.3% in the first quarter. Swiss National Bank now owns 28,000 shares of the company's stock valued at $324,000 after purchasing an additional 1,900 shares during the last quarter. CNA Financial Corp raised its position in shares of Sight Sciences by 16.8% during the first quarter. CNA Financial Corp now owns 16,383 shares of the company's stock worth $189,000 after acquiring an additional 2,356 shares during the last quarter. Amalgamated Bank bought a new position in shares of Sight Sciences during the first quarter worth about $31,000. Renaissance Technologies LLC raised its position in shares of Sight Sciences by 11.6% during the third quarter. Renaissance Technologies LLC now owns 31,586 shares of the company's stock worth $201,000 after acquiring an additional 3,286 shares during the last quarter. Finally, California State Teachers Retirement System raised its position in shares of Sight Sciences by 21.0% during the first quarter. California State Teachers Retirement System now owns 19,546 shares of the company's stock worth $226,000 after acquiring an additional 3,398 shares during the last quarter. 65.20% of the stock is owned by institutional investors and hedge funds.

Sight Sciences Stock Down 1.5 %


SGHT opened at $9.75 on Wednesday. Sight Sciences has a 1-year low of $5.35 and a 1-year high of $23.03. The stock's fifty day simple moving average is $7.41 and its 200 day simple moving average is $8.32. The company has a current ratio of 12.79, a quick ratio of 12.47 and a debt-to-equity ratio of 0.19. The stock has a market cap of $469.47 million, a PE ratio of -5.45 and a beta of 1.21.

Sight Sciences Company Profile

(Get Rating)

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists.

Recommended Stories

Analyst Recommendations for Sight Sciences (NASDAQ:SGHT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should you invest $1,000 in Sight Sciences right now?

Before you consider Sight Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sight Sciences wasn't on the list.

While Sight Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here